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Background: Manufacturers and promoters of various polyherbal bitters claim that, being of natural origin, they 
could be co-administered with therapeutic drugs with no adverse effects, and that it could be used to treat a wide 
array of ailments including diabetics. Most Nigerians use the bitters and their conventional drugs concurrently.   
Objectives: To assess the effects(s) or otherwise of the co-administration of two popular bitters in Nigeria market S-
bitter and Y-bitter with two therapeutic antidiabetic drugs glibenclamide and metformin on some liver and kidney  
biochemicals and lipid profile. 
Methodology: Therapeutic doses of glibenclamide, metformin and the bitters alone and a combination of the drugs 
and the bitters corresponding to the body weight of the rats were administered orally to different groups daily for 
fourteen days.  On the 15th day, the rats were sacrificed and plasma collected was analyzed for the hepatic 
biochemicals (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, albumin, total and direct 
bilirubin), lipid biochemical (high density lipid cholesterol, low density lipid cholesterol, total cholesterol and 
triglycerides) and renal biochemicals (creatinine and urea). 
Results: When metformin, glibenclamide and the bitters were administered alone, there was a marginal decrees in 
the levels of alanine aminotransferase, and a significant increase (p<0.05) in the plasma levels of creatinine and blood 
urea nitrogen.  A combination of the bitters with metformin and glibenclamide caused a significant decrease (P<0.05) 
in the levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and bilirubin, but there 
was an increase in the levels of total cholesterol, high density lipid cholesterol, low density lipid cholesterol, 
triglycerides and albumin. 
Conclusion: From the results, we conclude that the co-administration of the bitters with therapeutic drugs is 
hepatoprotective by reducing the levels of liver enzymes and bilirubin, and by increasing levels of lipid biochemicals, 
it could lead to the development of   heart disease. We therefore advise users of the bitters to do so separately and 
not in combination with conventional drugs. 
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1. Introduction 
Diabetes mellitus is a complex chronic illness requiring 
continuous medical care (WHO, 2014). As of 2013, 382 
million people had diabetes worldwide (IDF, 2016). The 
pancreas is a storage deport for digestive enzymes and 
hormone, among which is insulin which promotes 
uptake of glucose by most cells especially those of the 
liver, skeletal muscle and adipose tissues thus lowering 
plasma glucose concentration, (Rang et al, 2007). The 
complications of diabetes mellitus are morphological 
consequences of many altered metabolic pathways 
which may be associated with increased free radical, 
hepatic enzymes and plasma lipid activity, (Etim et al, 
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2011; Oberley, 1988). Alloxan, a β-cytotoxin produces 
massive destruction of the β-cells of the islet of 
Langerhans, resulting in decreased endogenous insulin 
release which leads to decrease glucose utilization by 
tissues and a resultant diabetic (hyperglycemia) 
condition (Rang et al, 2007). An abnormality in glucose 
metabolism influences liver function enzymes, lipid 
metabolism and other endogenous biochemicals (Etim et 
al, 2011).  
The bitters are galenical oral preparations made from a 
blend of various parts and fruits of plants. Manufacturers 
of the various bitters claim that, they cure a wide variety 
of ailments among which are kidney and bladder 
infections, normalize intestinal motility, lower blood 
sugar, act as digestive aid and detoxify the body, (Etim et 
al, 2016). Some researchers agree that some bitters have 
potent antidiabetic efficiency, (Jimmy and Udofia, 2014). 
The bitters are widely used for diabetic treatment in 
Nigeria (Jimmy and Udofia, 2014). Components of the 
bitters are known to interact with and influence the 
pharmacokinetics and blood glucose levels of 
therapeutic drugs, (Jimmy and Udofia, 2014; Etim et al, 
2016). 
Some enzymes act as indicators of disease states. 
Enzymes levels in the serum or plasma form an integral 
part of diagnosis. Increase in the level of enzyme in 
plasma is indicative of cell damage. Liver disease is the 
most important cause of increased alanine 
aminotransferase (ALT) and aspartate aminotrasferase 
(AST) activity. In hepatocellular injury or necrosis, there 
is leakage of cytoplasmic enzymes into the systemic 
circulation and as such the level of the enzymes in the 
plasma in higher (Hasper and Jorres, 2011; Etim et al, 
2013). 
Lipid profile which involve total cholesterols (TC), high 
density lipoproteins (HDL), low density lipoproteins 
(LDL), very low density lipoproteins (VLDL) and 
triglycerides (TG), serve as diagnostic indices in 
conditions such as chronic obstructive jaundice, 
hepatitis, coronary heart disease, while cholesterol is the 
major lipid constituent of arteriosclerotic plague, (Rang 
et al, 2007; Ekpo et al, 2007). 
Creatinine wich is derived from creatine and 
phosphocreatine is a major constituent of muscles. When 
creatinine is released from the muscle into plasma, it is 
excreted almost exclusively by the kidney through 
glomerular filtration process. It is neither re-absorbed, 
secreted, synthesized nor metabolized by the kidney 
hence the clearance of creatinine is equal to the 
glomerular filtration rate (GFR). A decrease in the GFR 
would result in an increase in the plasma creatinine 
concentration, thus the determination of the plasma 
creatinine concentration is used in the clinical evaluation 
of patients with suspected renal disease, (Onyeneke et al, 
2000; Marshal and Bangert, 2009). 
The end product of protein metabolism is urea and it is 
produced solely by the liver. After production, it travels 
through the blood and is excreted by the kidneys. 
Because the blood urea nitrogen (BUN) is completely 
filtered at the glomerulus of the kidneys, then 
reabsorbed and tubularly secreted within the nephrons, 
the concentrations of BUN reflect renal function. 
Hydration status, protein intake and some drugs which 
affect renal blood flow will affect the BUN of individuals 
(Etim et al, 2012). 
Since consumers of these bitters may do so concurrently 
with some therapeutic drugs, this study sought to assess 
the effect or otherwise on liver enzymes and other 
biochemicals, lipid profile, creatinine and urea levels in 
alloxan induced diabetic rats treated separately and 
concurrently with two brands of widely used bitters in 
Nigeria SB and YB and two popular therapeutic 
antidiabetics GLI and MET. The results obtained would 
enable us to ascertain the safety or otherwise of these 
act, and to advise consumers accordingly. 
2. Methodology 
2.1 Animals 
A total of sixty healthy albino rats of both sexes (Wister 
strain) weighing between 160 – 230 ± 21g were used in 
the study. They were maintained under standard 
environmental condition and had free access to food and 
water at the animal house, Department of Pharmacology 
and Toxicology, Faculty of Pharmacy, University of Uyo.  
Permission and approval for animal studies were 
obtained from College of Health Science, Animal Ethics 
Committee, University of Uyo. 
2.2 Induction of diabetes 
The animals were fasted overnight, and diabetes was 
induced by a single intraperitoneal injection of freshly 
prepared solution of alloxan (120 mg/kg body weight) in 
ice-cold 0.9% saline solution. The animals were allowed 
to drink 5% glucose solution overnight to overcome the 
drug-induced hypoglycemia (Okokon et al, 2009). 
Control groups both positive and negative were injected 
with normal saline alone.  
Seventy two hours after the administration of alloxan, 
the blood glucose levels of the alloxan treated rats was 
checked for the development of diabetes, and those with 
moderate diabetes having hyperglycemia (blood glucose 
level range above 200mg/dl) were considered as 
diabetic and used for the various drug combination 
treatment (Okokon et al, 2009).  
2.3 Experimental design 
The diabetic rats were divided into nine groups A to I, 
with six animals in each group. Eight groups were for the 
various drug combination treatment while the ninth 
group was the negative control and was treated with 
distilled water.  
A positive control group comprising six non-diabetic rats 
were treated with distilled water only and was used for 
comparison of the normal variation of the various 
biochemicals in rats (Okokon et al, 2009).   
2.4 Administration of test materials 
The various drugs and combinations were administrated 
daily for 14 days as shown in Table 1. At the end of 14 
days, the animals were sacrificed under chloroform 
anaesthesia and blood was collected by cardiac puncture, 
into EDTA tubes. The whole blood collected was allowed 
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to equilibrate with the anticoagulant. The blood was then 
centrifuged for 20 minutes at 5,000 rpm. The plasma was 
aspirated into sterile sample tubes and stored at -4oC for 
the various analysis. 
Table 1: Administration of test substances  
Group  Test substance administered 
A Glibenclamide alone 5mg/kg 
body weight 
B Glibenclamide 5mg/kg + S-bitters 
15ml/kg 
C Glibenclamide 5mg/kg + Y-bitters 
20ml/kg. 
D Metformin alone 15mg/kg 
E Metformin 15mg/kg + S-bitters 
15ml/kg 
F Metformin 15mg/kg + Y-bitters 
20ml/kg 
G S-bitter alone 15ml/kg 
H Y-bitter alone 20ml/kg 




(Positive control) distilled water 
3ml/kg 
 
2.5 Analysis of plasma:  
The prepared plasma was analyzed using BS – 120 
Chemistry Analyzer after mixing the plasma with 
different diagnostic kits and incubating at 37oC for time 
depending on the compound analyzed, following the 
methods as outlined in Clinical Chemistry Solutions 
Product List Mindray Brochure. The compounds were 
measured as follows; 
Hepatic Biochemicals: 
Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were measured using ALT and 
AST diagnostic kit according to International Federation 
of Clinical Chemistry and Laboratory Medicine (IFCC) 
without pyridoxal phosphate activation (Marshall and 
Bangert, 2009 ; Chemistry Solutions Brochure, 2012). 
The absorbance was read at 340nm against sample blank 
which automatically recorded the concentration of ALT 
and AST in international unit (U/L) 
Alkaline phosphatase (ALP) was measured using ALP 
diagnostic kit with the modified IFCC method. The 
absorbance was read at 405nm against sample blank and 
the concentration of ALP was recorded in international 
unit (U/L). 
Total and direct bilirubin (T-BIL. And D-BIL) were 
analyzed with the various diagnostic kit using the 
Diazotized Sulfonic Acid (DSA) method. The absorbance 
was read at 546nm against sample blank and the 
concentration of T-BIL and D-BIL recorded in µmol/L 
(Whitby et al, 1984). 
Albumin (ALB) was measured using Bromocresol Green 
Method (BCG). The absorbance was read at 578nm and 
the ALB concentration was recorded in g/L (Marshall 
and Bangert, 2009; Chemistry Solutions Brochure, 
2012). 
Lipids: 
High density lipid cholesterol (HDL-C) and low density 
cholesterol (LDL-C) were measured with the respective 
kits using the direct method by incubating for 5 minutes 
at 370C and measuring the absorbance at 600nm. HDL-C 
and LDL-C were given in mmol/L. 
Total Cholesterol (TC) was measured with TC diagnostic 
kit using Cholesterol oxidase-Peroxidase (CHOD-POD) 
method. The absorbance was read at 510nm against 
sample blank and the concentration of TC was recorded 
in mmol/L. 
Triglycerides (TG) was measured with TG diagnostic Kit 
using Glycerokinase Peroxidase –Peroxidase method 
(GPO-POD). The reagents and plasma were thoroughly 
mixed and incubated at 370C for 10 minutes. The 
absorbance was read at 510nm against sample blank, 
and the concentration of TG was recorded in mmol/L 
(Marshall and Bangert, 2009). 
Renal Biochemicals: 
Creatinine was measured with creatinine diagnostic kit 
using modified Jaffe method. The absorbance was 
measured at 510nm and creatinine concentration was 
given in µmol/L, while Urea  kit using Urease-glutamate 
Dehydrogenase  UV method at 340nm was used to 
measure urea (Marshall and Bangert, 2009; Onyeneke et 
al, 2003)    
2.6 Statistical analysis 
Data were expressed as mean ±SEM. Statistical 
comparisons between groups were performed using 
analysis of variance (ANOVA). Difference between mean 
were determined by Turky – Kramer pair-wise 
comparison test at a level of p<0.05 
3.  Results and Discussion 
The results for the administration of MET, GLI, the bitters 
and the various combination, for liver enzymes ALT, ALP 
and AST as well as bilirubin are given in Table 2. The 
values are compared to the positive control which were 
given neither the drug, the bitters nor their combination. 
When MET and GLI and the bitters were administered 
alone, there was a marginal decrees in the levels of ALT, 
but a combination of the bitters and the conventional 
drugs MET and GLI caused significant decrease (P<0.05) 
in the levels of ALT. The same trend was observed for 
ALP and AST (Table 2).  
These results suggest a hepatoprotective effect by 
components of the bitters and synergism in restoring 
liver function when used with therapeutic drugs (Kazim 
et al, 2015). MET, GLI, SB and YB when administered 
alone caused a significant decrease (P<0.05) in the levels 
of TBIL and CBIL (Table 2). Low levels of CBIL indicates 
that bile is properly excreted and these is no obstruction 
in the bile duct or gall bladder. Low levels of 
unconjugated bilirubin indicates that less haemoglobin is 
being destroyed or that the liver is actively treating the 
 Etim et al, Afr. J. Pharmacol. Ther. 2016. 5(4): 235-240 
 
 
A KeSoBAP Publication ©2016. All rights reserved.  ISSN 2303-9841 
238 
haemoglobin it is receiving. (Grazisdei 2011).  There was 
no effect on the levels of plasma albumin when the drugs 
and bitters were administered as mono-therapy and in 
combination with each other as shown in Table 2. 
There was an increase in the levels of total cholesterol, 
HDL, LDL and triglycerides when MET, GLI, SY, YB and 
their various combinations were administered to the 
diabetic rats compared to negative controls (Table 3). 
Clinical knowledge of the levels of plasma lipids is an 
important biochemical tool in the toxicity or beneficial 
effects of foreign compounds. Plasma lipids are 
predominantly resident in body tissues. The 
physiological and pathological state of body tissues is 
highly associated with metabolism, level of plasma lipids 
and lipid peroxidation (Etim et al, 2011). In situation 
where there is high activity of these lipids in the body 
tissues due to oxidative damage, associated with lipid 
metabolism, the administration of antioxidants 
ameliorates tissue dysfunction (Robert, 2012).    
Hyperlipidemia is one of the risk factors for coronary 
heart disease while cholesterol is the major lipid 
constituent of atherosclerotic plague (Etim et al, 2011). 
The gradual increase in the lipid profile of diabetic rats 
treated with GLI, MET, SB, YB, and their combination and 
negative control indicates that there might be a gradual 
buildup of lipid which may result in coronary heart 
disease (Ekpo et al, 2007). The increase in the level of 
triglyceride in diabetic rats is because of the destruction 
of the acinar cells in pancreas responsible for the 
secretion of pancreatic lipase essential for lipid 
digestion. The high level of the various lipids indicates 
that the antidiabetic drugs and the bitters alone and in 
combination do not have the ability of rapid regeneration 
of the acinar cells (Hensley et al, 2000).  
 
Table 2: Plasma level of liver enzymes and biochemicals in rats treated with therapeutic drug (GLI and MET), the bitters 
(SB and YB) and a combination of therapeutic drugs with the bitters. 
 ALT (U/L) TBIL(µmol/L) DBIL(µmol/L) ALP (U/L) AST (U/L) ALB (g/L) 
MET 107.2±6.11 8.78±2.87 4.65±1.77 612.5±16.71 322.4±11.37 38.40 ±2.11 
MET+SB 96.3±20.91 10.44±1.63 9.31±2.8 491.9±18.4 186.85±16.5 37.80±1.20 
MET+YB 129.1±1.56 10.53±1.01 5.67±1.10 460.5±11.32 239.9±3.91 38.00±1.00 
GLI 111.45±2.41 7.62±0.05 5.79±0.35 998.6±13.51 334.65±0.15 38.70±0.51 
GLI+SB 66.5±6.31 10.82±2.15 8.06±2.65 433.3±20.52 250.65±23.65 38.70 ± 0.90 
GLI+YB 67.2±1.90 10.36±1.12 8.66±0.46 402.8±9.801 226.05±11.45 38.40±1.00 
SB 101.3±8.55 6.71±0.41 4.85±0.21 582±16.13 297.15±18.5 38.25±.25 
YB 111.75±2.75 7.46±1.42 4.81±0.49 699.4±18.11 355.7±9.1 37.95±1.33 
CON NC 96.4±6.71 12.94±1.33 9.06±2.13 579.2±7.63 203.30±6.11 33.00±3.12 
CON PC 121.16±2.11 12.70±1.91 9.93±2.00 736.7±8.71 168.7±3.7 35.80±1.20 
 Values are expressed as mean ± SEM significance relative to positive control P<0.05, (n=6) 
 
Table 3: Lipid profile of rats treated with therapeutic drug (GLI and MET), the bitters (SB and YB) and a combination 
of therapeutic drugs with the bitters. 
Material administered 
Lipid profile (mmol/L) 
TC HDL –C LDL – C TG 
GLI alone 2.78± 0.45 1.02 ±0.07 1.14±0.10 1.27±0.14 
GLI + SB 2.93 ± 0.91 1.51 ±0.17 0.93±0.30 1.30±0.17 
GLI + YB 2.32 ± 0.42 1.40±0.07 1.05± 0.15 1.30±0.14 
MEt alone 2.11 ±0.63 1.32±0.17 1.22± 0.15 1.21±0.11 
MET + SB 2.42±0.63 1.11±0.21 0.96± 0.27 1.05±0.09 
MET + YB 3.21±0.93 1.15±0.15 1.04±0.11 1.51±0.04 
SB alone 2.17±0.40 1.19±0.18 0.86±0.43 1.45±0.49 
YB alone 2.29± 0.10 1.11±0.21 1.18±0.11 1.25±0.14 
Distilled water(NC) 2.67 ±0.43 1.48±0.23 1.61±0.06 1.77±0.12 
Distilled water (PC) 1.31 ± 0.32 0.90± 0.01 0.56±0.01 0.75±0.31 
     Values are expressed as mean ± SEM significance relative to positive control p<0.05,(n=6)  
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Table 4: Plasma levels of creatinine and urea in rats treated with therapeutic drug (GLI and MET), the bitters (SB and 
YB) and a combination of therapeutic drugs with the bitters.  
 CREA – J UREA 
MET 77.90±2.18 25.40±1.33 
MET+SB 65.25±3.75 12.36±2.45 
MET+YB 83.70±2.11 29.87±3.13 
GLI 81.20±3.10 10.35±1.50 
GLI+SB 59.45±2.95 10.35±2.20 
GLI+YB 73.20±6.52 12.25±3.21 
SB 76.15±3.65 16.36±3.41 
YB 63.30±3.40 22.94±3.54 
CON NC 51.40±2.11 8.41±1.36 
CON PC 63.30±3.40 10.32±1.10 
      Values are expressed as mean ± SEM significance relative to positive control p<0.05, (n=6)  
There was a significant increase in the plasma levels of 
creatinine and BUN when GLI, MET, SB and YB were 
administered as monotherapy (Table 4). This suggest a 
decrease in glomerula filtration and an adverse effect on 
the kidney (Etim et al, 2013). When GLI and MET were 
respectively administered with SB, the levels of both 
creatinine and BUN returned to normal. This was not the 
case when they were administered with YB. This suggest 
that there may be a component of SB which reacts with 
MET and GLI respectively to enhance kidney functions. 
4. Conclusion 
The results vary with the parameter studied. 
Combination of the bitters with therapeutic drugs cause 
synergism in liver protection, while there was increase 
in lipid profile which is a pointer to cardiovascular 
diseases. With renal efficacy, one bitter enhances renal 
function while the other had no effect. With the high 
number of bitters flooding our markets, and the high 
level of uncertainty of actions in various organs, we 
conclude that it is best to administer the bitters separate 
from therapeutic drugs. 
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